![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Indian API Manufacturer Called Out for Numerous Violations
Indian API Manufacturer Called Out for Numerous Violations
June 19, 2018
The FDA cited Reliance Life Sciences for a long list of deficiencies observed during an inspection of the API manufacturer’s facility in Navi Mumbai in December.
The investigator listed 18 violations in a Form 483, including batch failures, unexplained discrepancies, quality unit shortcomings and a lack of vendor qualification.
For example, the firm failed to reject material that was determined to be out-of-specification and used it in the manufacturing of a product. It also determined the root cause behind several OOS instances without providing any scientific rationale.
Upcoming Events
-
21Oct